﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Infectious Diseases</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Infectious Diseases"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.14.26368125v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.13.26367169v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.14.26368122v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.16.26367621v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.13.26368071v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.12.26367925v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.13.26367559v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.11.26367863v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.11.26367824v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.11.26367525v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.11.26367839v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.11.26367845v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.08.26367568v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.10.26367744v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.10.26367219v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.10.26367734v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.09.26367673v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.09.26367649v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.08.26367564v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.06.26367448v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.06.26367472v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.07.26367494v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.07.26367521v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.06.26367422v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.06.26365637v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.06.26367418v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.06.26367404v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.11.05.26367381v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.14.26368125v1?rss=1">
<title>
<![CDATA[
Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.14.26368125v1?rss=1
</link>
<description><![CDATA[
Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed
]]></description>
<dc:creator><![CDATA[ Sharma, A., Nakiyingi, L., Janeva, E. J., Guevarra, K., Nate, W., Nabawanuka, E., Shankman, R., Dhamdhere, R., Astorga, G., Joloba, M. L., Ellner, J., Madabhushi, A., Xie, Y. L. ]]></dc:creator>
<dc:date>2026-11-17</dc:date>
<dc:identifier>doi:10.64898/2026.11.14.26368125</dc:identifier>
<dc:title><![CDATA[Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.13.26367169v1?rss=1">
<title>
<![CDATA[
A rapid and sensitive Loop-Mediated Isothermal Amplification (LAMP) assay for detection of mecA antibiotic resistance gene in clinical and food bacterial isolates 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.13.26367169v1?rss=1
</link>
<description><![CDATA[
An advanced LAMP assay targeting the mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) was developed and validated using clinical and foodborne S. aureus isolates. Reference strains, including both methicillin-sensitive and methicillin-resistant S. aureus, were used to evaluate and optimize assay performance. With the newly designed ID16 LAMP primer set, the detection limit for mecA was 15 fg/L of total genomic DNA, equivalent to 5 copies/L, and the assay turnaround time was only 25 min. All mecA-positive isolates identified by conventional qPCR were successfully detected by the LAMP assay. Overall, the developed LAMP method provides a rapid, highly specific, and sensitive alternative for mecA detection.
]]></description>
<dc:creator><![CDATA[ Baldenweck, L., Djisalov, M., Pinamonti, D., manzano, M., Gadjanski, I., Vidic, J. ]]></dc:creator>
<dc:date>2026-11-17</dc:date>
<dc:identifier>doi:10.64898/2026.11.13.26367169</dc:identifier>
<dc:title><![CDATA[A rapid and sensitive Loop-Mediated Isothermal Amplification (LAMP) assay for detection of mecA antibiotic resistance gene in clinical and food bacterial isolates]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.14.26368122v1?rss=1">
<title>
<![CDATA[
Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.14.26368122v1?rss=1
</link>
<description><![CDATA[
Public health organizations can benefit greatly from infectious disease epidemic forecasting to guide and support interventions and policies that reduce morbidity. However, accurate and reliable epidemic forecasting remains notoriously challenging and is an evolving field in which new scientific advances continue to support forecasting efforts. Computational models that underpin artificial intelligence (AI) models are promising developments that may improve seasonal epidemic forecasting. This study aims to compare the performance of a selection of AI models previously identified as well adapted to epidemic forecasting, including machine learning (XGBoost), deep learning models (Long Short-Term Memory (LSTM), Gated Recurrent Unit (GRU), Transformer), time-series foundation model (Chronos), and a hybrid model: physics-informed neural networks (PINNs), against statistical models (Autoregressive Integrated Moving Average (ARIMA), Prophet) and a compartmental epidemiological model (CEM) in seasonal epidemic forecasting across Canada. The study uses weekly positivity-rate incidence of seasonal influenza A across eight Canadian provinces during the 2025/2026 season as a test case. Each model generated short-term (up to 5 weeks ahead) forecasts independently for each province from October 11, 2025, to March 28, 2026. We evaluated performance using mean absolute error (MAE) for each province. Our results show that AI models, specifically GRU, Transformer, and Chronos models, achieve lower MAE than CEM in four of eight provinces (Alberta, British Columbia, Prince Edward Island, and Saskatchewan). Meanwhile, CEM and ARIMA outperform all AI models in three provinces (Ontario, Quebec, Manitoba) and one province (Nova Scotia), respectively. Furthermore, data pooling strategies that leverage multi-province data for the target virus or multi-virus data within individual provinces greatly improve deep learning models, and Chronos performs well under zero-shot forecasting in British Columbia. In contrast, Prophet always has the highest MAE, and PINN is worse than CEMs. Overall, AI models performed comparably to, or slightly better than, CEMs. However, these modest gains may not offset their lack of interpretability, high computational costs, and reliance on the specialized expertise required for implementation. We therefore conclude that AI models are best as a complement, rather than a replacement, to CEMs, which remain crucial for interpretability and informing decision-making.
]]></description>
<dc:creator><![CDATA[ Benteke, B. L., Yusuf, W., Cojocaru, M. G., Champredon, D. ]]></dc:creator>
<dc:date>2026-11-17</dc:date>
<dc:identifier>doi:10.64898/2026.11.14.26368122</dc:identifier>
<dc:title><![CDATA[Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.16.26367621v1?rss=1">
<title>
<![CDATA[
Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025). 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.16.26367621v1?rss=1
</link>
<description><![CDATA[
Introduction: The introduction of pneumococcal conjugate vaccines resulted in a decline in invasive pneumococcal disease (IPD). Nevertheless, recent studies report a re-emergence of vaccine-included serotypes. Aim: To describe the recent re-emergence of serotype 14 IPD among adults in Catalonia and to investigate the factors underlying its resurgence. Methods: We analysed two collections of adult IPD isolates: a historical series from Hospital Universitari de Bellvitge (1996-2025) and a multicentre series from seven tertiary hospitals in Catalonia (2023-2025). Isolates were serotyped (Quellung) and genotyped by PFGE/MLST (1996-2022) or Illumina sequencing (2023-2025). Clinical data were retrospectively collected. Results: The historical series showed that, after peaking in 2009, serotype 14 frequency gradually declined, with only -4 cases reported annually between 2016 and 2020. However, the number of serotype 14 isolates increased again in 2025, reaching 11.0% of all isolates at HUB and 10.8% across Catalonia. Genomic data showed that this increase involved multiple previously circulating lineages (GPSC6, GPSC18, GPSC16 and GPSC39), with no dominant clone. Analysis of the capsular locus revealed substantial genetic diversity, with no association between capsular variants and either lineage or year of isolation. A substantial proportion of patients (56.3%) had multiple comorbidities and only 18.8% were appropriately vaccinated. Discussion: The re-emergence of serotype 14 was not associated with a novel lineage or capsular variant. Instead, it may reflect a combination of post-pandemic transmission changes, higher-valency paediatric vaccines, and natural fluctuations in serotype circulation. These findings highlight the limits of herd protection and underscore the need to strengthen adult vaccination, particularly among at-risk populations.
]]></description>
<dc:creator><![CDATA[ Gonzalez-Diaz, A., Broner, S., Calvo-Silveria, S., Grau, I., Quesada, M. D., Belles, A., del Corral, E., Pico-Plana, E., Clapes, E., Vinado, B., Berbel, D., Llopis, M. A., Dominguez, M. A., Marti, S., Camara, J., Ciruela, P., Ardanuy, C. ]]></dc:creator>
<dc:date>2026-11-17</dc:date>
<dc:identifier>doi:10.64898/2026.11.16.26367621</dc:identifier>
<dc:title><![CDATA[Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025).]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1">
<title>
<![CDATA[
Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1
</link>
<description><![CDATA[
Background: Tuberculosis (TB) notifications have increased in several high-income countries since 2020. Proposed explanations include pandemic related disruption of treatment for latent tuberculosis, changes in population composition, and immune dysfunction following SARS CoV 2 infection. We assessed whether TB presentations increased during the pandemic era and then tested whether community SARS CoV 2 activity was followed by increased mycobacterial disease. Methods: We conducted a population-based ecological time-series study of first TB- and nontuberculous mycobacterial (NTM)-coded hospital, emergency-department and ambulatory clinic presentations in the Greater Toronto/Hamilton Area Plus (GTHA+), Ontario (2024 population approximately 11.2 million), from April 2011 through March 2024. NTM served as a comparator because it shares diagnostic pathways with TB but differs epidemiologically. Negative binomial projection and full-series models estimated pandemic-era changes under three alternative trend assumptions. Distributed lag non linear models estimated cumulative rate ratios for standardized community viral activity over 0 to 12 weeks; sensitivity analyses extended the maximum lag to 26 and 52 weeks. Influenza and respiratory syncytial virus (RSV) were prespecified comparators; data for five additional viral exposures were obtained after the primary analysis was completed and analysed as exploratory comparisons. Results: We identified 3,985 first TB-coded and 5,214 first NTM-coded acute-care presentations. Across six models, estimated pandemic-era TB increases ranged from 3% to 22%. No model suggested an increased in NTM. SARS-CoV-2 activity was not positively associated with TB (cumulative rate ratio per 1-SD increase over 0 to 12 weeks 0.909, 95% CI 0.822 to 1.006) or NTM (0.953, 0.868 to 1.047). No positive associations were identified in subgroup analyses or with maximum lags of 26 or 52 weeks. Influenza was not associated with either outcome. RSV was associated with TB and NTM; only the RSV/NTM association met the Bonferroni threshold among the prespecified comparisons, and no exploratory associations met the experiment wide threshold. Conclusions: We identified a modest pandemic era increase in TB-coded acute-care presentations in Ontario, Canada, although its estimated size depended on assumptions about underlying trends. NTM-coded presentations did not increase. Community SARS-CoV-2 activity was not positively associated with subsequent TB or NTM presentations at lags of up to one year and did not provide a temporal explanation for the population-level TB increase. Individual-level effects cannot be excluded.
]]></description>
<dc:creator><![CDATA[ Wilson, N. J., Tuite, A., Lee, C. E., Berkowitz, R. J., Wiebe, B., Hall, J., Boushy, D., Fisman, D. ]]></dc:creator>
<dc:date>2026-11-17</dc:date>
<dc:identifier>doi:10.64898/2026.11.14.26367737</dc:identifier>
<dc:title><![CDATA[Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.13.26368071v1?rss=1">
<title>
<![CDATA[
Diagnostic performance of rK28- and rK39-based rapid diagnostic tests for Visceral Leishmaniasis in Kenya: Implications for the national diagnostic algorithm 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.13.26368071v1?rss=1
</link>
<description><![CDATA[
Background Visceral Leishmaniasis (VL) is a neglected tropical disease (NTD) caused by Leishmania infantum and L. donovani and transmitted by an infectious bite of a female phlebotomine sandfly. The disease disproportionately affects impoverished and underserved populations, where inadequate access to healthcare. In Kenya, 11 out of the 47 counties are endemic for VL, a fatal disease if untreated. Parasitological methods remain the gold standard for diagnosing VL, however they are invasive and require specialised training and equipment. Serological tests such as Rapid Diagnostic Tests (RDTs) are widely used for screening but can still report positive results way after treatment due to persistence of anti-VL antibodies. It is recommended that VL diagnosis follows an algorithmic approach. This study evaluated diagnostic performance of rK28 and rK39 RDTs (Kala-azar Detect and IT Leish) in various algorithmic combinations against a composite reference standard. Methodology We evaluated rK28 and Kala-azar Detect along with rK39 IT-Leish as index tests, and Direct Agglutination Test (DAT) as the reference test. Participants were recruited from seven health facilities in Marsabit and Turkana counties. Blood samples were collected together with patient demographic data. Treatment followed the national algorithm and health facility routine procedures. Diagnostic test performance was assessed individually, in parallel, and sequential algorithmic combinations. Specificity, sensitivity, balanced accuracy, negative and positive predictive values were statistically estimated. Results A total of 398 participants were recruited, with most reported clinical symptoms being fever and splenomegaly. Individually, the rK28 kit demonstrated 96% sensitivity, 86% specificity, and 91.2% balanced accuracy (BA). The rK39 IT-Leish had 87% sensitivity, specificity 93%, and BA of 90.4%, while Kala-azar Detect had 67% sensitivity, 91% specificity and 79% BA. IT Leish to rK28 algorithm based on negatives had highest BA (90%), with 92% sensitivity and 88% specificity, while rK28 to Kala-azar detect algorithm based on positives showed the lowest BA (80%) with 65% sensitivity and 94.1% specificity. Discussion The rK28 RDT demonstrated high sensitivity (96-98%) and moderate specificity (72-86%), findings broadly consistent with reports elsewhere. In contrast, the rK39-based tests showed higher specificity (91-93%) but lower sensitivity (67-87%), limiting their effectiveness in elimination programs. Parallel testing algorithms combining rK28 and rK39 RDTs improved sensitivity up to 97.7%, whereas sequential approaches increased specificity at the expense of sensitivity when compared to rK28 alone. These approaches were more balanced as compared to sequential which increased overall specificity and reduced sensitivity. This flexibility in combinations provides more options for elimination programs. The performance of rK28 gives it an advantage over rK39 kits, especially with IT Leish facing stockouts. While the study faced limitations including lack of PCR data leading to reliance on DAT as the reference standard, and underpowered secondary analyses, the findings provide strong preliminary evidence guiding national algorithm, supply chain, and policy decisions that may accelerate VL elimination. Conclusion The findings demonstrate that diagnostic algorithms incorporating rK28 provide robust performance for VL diagnosis. They support consideration of rK28 diagnostic kit for VL diagnostic algorithms enhancing case detection for control and elimination efforts in Eastern Africa
]]></description>
<dc:creator><![CDATA[ Matoke-Muhia, D., Tuluso, M., Kimemia, B. B., Osero, B., Kamau, L., Ndungu, J. M., Ofwete, R., Thiongo, K., Maranga, D. ]]></dc:creator>
<dc:date>2026-11-16</dc:date>
<dc:identifier>doi:10.64898/2026.11.13.26368071</dc:identifier>
<dc:title><![CDATA[Diagnostic performance of rK28- and rK39-based rapid diagnostic tests for Visceral Leishmaniasis in Kenya: Implications for the national diagnostic algorithm]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-16</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.12.26367925v1?rss=1">
<title>
<![CDATA[
Shifting source hubs and the factors associated with cross-country Zika virus transmission: a phylogeographic network analysis, 2012-2025 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.12.26367925v1?rss=1
</link>
<description><![CDATA[
Background Zika virus local transmission has been reported in at least 97 countries and territories, but the sources, routes, and determinants of cross-country spread remain incompletely understood. We reconstructed a phylogeographic network, characterized source activity across epidemic phases, and examined factors associated with identified cross-country transmission events. Methodology/Principal Findings We analyzed a time-scaled Nextstrain phylogeny of 1,043 Zika virus genomes collected between February 2013 and March 2026. Parent-child branches assigned to different locations were screened and consolidated into 81 source-destination-year events involving 39 locations. Network analysis characterized temporal and geographic patterns, routes, hubs, and communities. For the analysis of associated factors, 68 events with complete covariate data were compared, using mixed-effects models, with eligible year-matched control records for which no event was identified, with all 68 events retained and a new control set drawn in each of 200 iterations. Asia contributed the earliest event, from Thailand in 2012. Most events occurred within the Americas (79.0%) and were concentrated during 2014-2016, with Brazil as the principal source hub. All six events from 2019 onward originated from Thailand or India and reached destinations in Asia, Europe, and Africa. Thailand's source activity spanned 2012-2025. Event identification was positively associated with high source-country incidence (odds ratio [OR], 2.66; 95% confidence interval [CI], 1.39-9.69), greater air travel (OR, 2.52; 95% CI, 1.58-5.67), and higher destination-country GNI per capita (OR, 1.70; 95% CI, 1.20-4.50). It was negatively associated with greater geographic distance (OR, 0.11; 95% CI, 0.02-0.20) and higher source-country GNI per capita (OR, 0.64; 95% CI, 0.45-0.94). Fourteen source countries showed elevated residual source propensities, with Brazil and Thailand among the highest. Conclusions/Significance The transmission network showed a shift in dominant source hubs, from early activity in Asia to the Americas during the 2014-2016 epidemic and back to Asia in recent years. High source-country incidence, greater air travel, and shorter distance can help identify country pairs requiring closer surveillance, alongside established routes in the Americas and persistent or emerging Asian sources, particularly as El Nino may increase vector-borne transmission potential in 2026-2027.
]]></description>
<dc:creator><![CDATA[ Pang, M., Bu, X., Liu, Q., Li, C., Chan, N., Ji, H., Qi, X., Huang, Y. ]]></dc:creator>
<dc:date>2026-11-15</dc:date>
<dc:identifier>doi:10.64898/2026.11.12.26367925</dc:identifier>
<dc:title><![CDATA[Shifting source hubs and the factors associated with cross-country Zika virus transmission: a phylogeographic network analysis, 2012-2025]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.13.26367559v1?rss=1">
<title>
<![CDATA[
Pseudomonas aeruginosa in bronchiectasis: unmasking population diversity and antimicrobial resistance in the Australian context 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.13.26367559v1?rss=1
</link>
<description><![CDATA[
ABSTRACT Background: Pseudomonas aeruginosa infections in bronchiectasis airways result in poorer lung function, advanced lung lobe involvement, worsened life quality, and higher hospitalisation rates. Despite high prevalence, little is known about P. aeruginosa population genomics, antimicrobial resistance (AMR) rates, persistence, and transmission dynamics in Australians with bronchiectasis. Methods: P. aeruginosa (n=137) isolated between 2009 and 2025 from 59 Australians with bronchiectasis underwent antimicrobial susceptibility testing against 11 antipseudomonal drugs, whole-genome sequencing, comparative genomics, and in silico AMR determinant identification. Data were integrated with 4,575 publicly available bronchiectasis-derived P. aeruginosa genomes to determine global phylogenomic and AMR determinant patterns. Results: High AMR rates were identified in the Australian isolates, with 75.9% resistant to at least one antimicrobial, 19.7% multidrug-resistant, and 9.5% extremely drug-resistant. AMR rates were highest (64.2%) for ciprofloxacin and cefepime (44.5%), and lowest for piperacillin/tazobactam (8.8%) and colistin (0.7%). Phylogenomics uncovered several instances of within-host evolution, hypermutation, persistence, and multi-lineage infections. Of the fifty-seven identified multilocus sequence types (STs), seven (12.3%) were novel, five were high-risk international clones (ST274 [6.6%], ST395 [0.7%], ST244 [0.7%], ST277 [0.7%], ST298 [0.7%]) and three were common global clones (ST253 [5.1%], ST155 [3.6%], ST260 [0.7%]). No high-risk AMR-conferring mobile genetic elements were seen, although numerous chromosomal AMR determinants were identified. AMR determinant prevalence was consistent with the global dataset, with no evidence of geographic clustering. Conclusions: Our study provides critical insights into P. aeruginosa diversity in Australians with bronchiectasis. High AMR rates and chronic colonisation highlight the need to improve diagnostics, antimicrobial stewardship measures, and infection control practices in this neglected clinical cohort.
]]></description>
<dc:creator><![CDATA[ Strickland, K. R., Baird, T., Burr, L. D., Dunn, E. M., Littlejohn, M. L., Davies, J. L., Bashford, J. J., Burke, A., Evans, I., Christensen, J., Brock, J., McIntosh, L., Price, E. P., Sarovich, D. S. ]]></dc:creator>
<dc:date>2026-11-15</dc:date>
<dc:identifier>doi:10.64898/2026.11.13.26367559</dc:identifier>
<dc:title><![CDATA[Pseudomonas aeruginosa in bronchiectasis: unmasking population diversity and antimicrobial resistance in the Australian context]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.11.26367863v1?rss=1">
<title>
<![CDATA[
Genomic diversity of respiratory pathogens in clinical versus community surveillance: a comparative analysis of SARS-CoV-2, RSV, and influenza viruses in Washington State 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.11.26367863v1?rss=1
</link>
<description><![CDATA[
BackgroundGenomic surveillance of respiratory viruses typically relies on sequences from individuals seeking health care, and whether these sequences represent the viruses circulating in the community is not well-characterized. We aimed to compare the diversity, proportion, and dynamics of influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 between clinical and community samples.

MethodsIn this retrospective comparative genomic analysis, we used whole-genome sequences from community-based surveillance studies in the Seattle area, and clinical sequences from the Washington State Department of Health. We compared clade proportions and dynamics, sequence-cluster diversity, non-synonymous mutations, and Ct values between clinical and community samples.

FindingsWe analyzed 538 RSV sequences collected between 2019 and 2021 (278 community, 260 clinical), 1506 influenza sequences (260 community, 1246 clinical) between 2019 and 2020, and 8660 SARS-CoV-2 sequences (5923 community, 2737 clinical) from 2020 to 2022. Clade proportions did not differ between clinical and community samples for RSV or influenza, but differed for SARS-CoV-2: clades 21J (Delta) and 21K (Omicron BA.1) were more frequent in community samples and clade 22B (Omicron BA.5) in clinical samples. SARS-CoV-2 clinical sequence clusters were more diverse than community clusters, whereas RSV and influenza showed no significant difference. Several spike mutations associated with monoclonal antibody resistance were more prevalent in community samples for SARS-CoV-2. Ct values were lower in clinical samples for multiple SARS-CoV-2, RSV, and influenza clades.

InterpretationSeasonal respiratory viruses had similar dynamics and diversity in clinical and community samples, whereas pandemic SARS-CoV-2 differed between settings. Genomic surveillance programs should combine clinical and community sampling, particularly during pandemics in order to better capture viral diversity.

FundingThis analysis was funded by the Washington State Department of Health Northwest Pathogen Genomics Center of Excellence (WA DOH contract number HED29377-1, federal grant number NU50CK000630 to University of Washington). The underlying studies were funded by Gates Ventures.

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSGenomic surveillance of respiratory viruses expanded substantially during the COVID-19 pandemic and has since been extended to respiratory syncytial virus (RSV) and influenza, but most sequences come from people who sought medical care. We searched PubMed for studies published in English up to September 2026 using combinations of terms "genomic surveillance", "community surveillance", "respiratory syncytial virus", "influenza", "SARS-CoV-2", "whole genome sequencing", and included studies that sequenced respiratory viruses from defined clinical or community populations. Previous work has sampled hospitalized patients, sequenced random positive specimens, or sequenced wastewater, and has shown that such data can track variant emergence, clade replacement, and nosocomial transmission. However, few studies compared clinical and community sampling for the same virus in the same population and period, so it remains unclear whether clinically derived sequences represent the viruses circulating in the community.

Added value of this studyTo our knowledge, this is the first study to compare viral diversity between clinical and community sampling for three respiratory viruses in the same region and overlapping time periods. Using more than 10,000 whole genomes from community-based surveillance studies and state clinical surveillance in Washington State, we found that clade proportions and dynamics were similar between sources for RSV and influenza, but differed for SARS-CoV-2. At finer genetic resolution, clinical SARS-CoV-2 sequences formed more diverse clusters than community sequences, and several spike mutations associated with monoclonal antibody resistance were more prevalent in community samples.

Implications of all the available evidenceFor seasonal respiratory viruses, sampling people who seek care appears to capture much of the diversity circulating in the community, which may allow surveillance programs with limited resources to rely on clinical specimens. In contrast with seasonal circulation in a population with some pre-existing immunity, during pandemic-level transmission, when very large numbers of people in a largely susceptible population are infected over a short period, clinical and community samples are not interchangeable, and programs that sequence only clinical specimens risk missing variants circulating in the community, including mutations relevant to antiviral and monoclonal antibody resistance. These differences may partly reflect the much larger number of SARS-CoV-2 genomes available, as well as heterogeneous mixing and co-circulation of multiple variants during the pandemic. Surveillance programs should therefore combine clinical and community sampling, and future studies should test whether these patterns hold in other regions, seasons, and pathogens.
]]></description>
<dc:creator><![CDATA[ Kirsch, J. M., Elias-Warren, A., Frisbie, L., Lockwood, C., Weil, A. A., Black, A., Chu, H. Y., Roychoudhury, P. ]]></dc:creator>
<dc:date>2026-11-13</dc:date>
<dc:identifier>doi:10.64898/2026.11.11.26367863</dc:identifier>
<dc:title><![CDATA[Genomic diversity of respiratory pathogens in clinical versus community surveillance: a comparative analysis of SARS-CoV-2, RSV, and influenza viruses in Washington State]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.11.26367824v1?rss=1">
<title>
<![CDATA[
Optimizing dosing strategies for children with leprosy: A weight-banded dosing approach 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.11.26367824v1?rss=1
</link>
<description><![CDATA[
BackgroundDosing guidance for children with leprosy remains operationally challenging. For children under 10 years of age, current WHO recommendations rely on mg/kg dosing of the three separate components of leprosy multidrug therapy, which are difficult to implement in routine care and may result in inconsistent drug exposures. Weight-banded dosing offers a pragmatic alternative that better aligns with pharmacokinetic principles and existing drug formulations.

MethodologyA pharmacokinetic simulation study was conducted to develop harmonized weight-banded dosing regimens for rifampicin, clofazimine, and dapsone in children aged 2 to <10 years. Using the WHO dosing tool, drug exposures across harmonized weight bands were simulated and adult-equivalent systemic exposure (80- 125% of adult area under the concentration-time curve) targeted. Predicted exposures were contextualized against safety reference regimens used in tuberculosis meningitis, multidrug-resistant tuberculosis, and leprosy. An iterative review process involving the WHO Technical Working Group on leprosy in children ensured clinical and operational feasibility.

ResultsProposed weight-banded multidrug therapy regimens achieved adult-equivalent exposures across most weight bands. Predicted exposures modestly exceeded 125% of adult levels at the lower end of selected weight bands but remained well below safety benchmarks, namely exposures associated with daily rifampicin therapy for tuberculosis meningitis and clofazimine regimens for multidrug-resistant tuberculosis. Dapsone exposures were comparable to those achieved with current leprosy dosing. The existing 10-14-year-old child MDT blister pack could be used without modification in children weighing 25-39.9 kg and with limited tablet or gel capsule removal in children weighing 6-24.9 kg.

ConclusionsA harmonized weight-banded dosing strategy was developed that enables effective, practical dosing of leprosy multidrug therapy in children under 10 years using existing free-of-charge blister packs provided through WHO. This approach improves dosing consistency, supports programmatic implementation, and provides a rational interim solution while child-friendly formulations are being developed.

Author SummaryLeprosy continues to affect children in many low-resource settings, yet guidance on how to dose treatment in younger children remains limited. Current recommendations often require clinicians to calculate mg/kg doses, which can be difficult in practice and may not match the oral formulations that are available.

In this study, we used computer-based simulations to develop a simplified dosing approach for the three drugs used to treat leprosy. We showed that grouping children into weight bands, rather than calculating individual doses, can achieve drug exposures similar to those seen in adults, where treatment is known to be effective. Importantly, we found that these doses can be delivered using existing pre-packed treatment kits by removing selected dose units, making this approach practical in routine care.

This work provides a more straightforward and reliable way to treat children with leprosy, reducing the burden on clinicians and improving access to treatment. However, challenges remain, including the lack of child-friendly formulations and limited data on how these drugs behave in children. Further studies are needed to improve treatment for this vulnerable population.
]]></description>
<dc:creator><![CDATA[ van Dyk, J., Masini, T., Lambert, S. M., Darlong, J., Deps, P. D., Nobre, M. L., van Brakel, W., Hill, B., Timalsina, A. B., Mane, S. S., Modali, S. A., Malik, P., Lal, V., Wasmann, R. E. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.11.26367824</dc:identifier>
<dc:title><![CDATA[Optimizing dosing strategies for children with leprosy: A weight-banded dosing approach]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.11.26367525v1?rss=1">
<title>
<![CDATA[
Altered herpesvirus-specific immune response is associated with long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.11.26367525v1?rss=1
</link>
<description><![CDATA[
Long COVID is associated with persistent immune dysregulation, but whether immunity to latent viruses is also altered remains unclear. We profiled herpesvirus-specific antibodies and T-cell responses in people with long COVID and recovered convalescent controls at 4, 8 and 24 months after SAR-CoV-2 infection. Overall antibody reactivity and abundance against cytomegalovirus (CMV) and Epstein-Barr virus (EBV), responder frequencies and circulating B-cell subsets were broadly preserved, but early antibody avidity and virus-specific CD4 response magnitude were reduced. Neither viruss nucleic acid was detected in plasma or stool at 4 or 8 months. Here, we show that long COVID is associated with selective, time-dependent alteration of herpesvirus-specific immune memory, including relatively preserved or enhanced CD8 responses and greater representation of selected herpesvirus-associated T-cell receptor clonotypes. Together, these findings indicate altered herpesvirus-specific antibody quality despite broadly preserved antibody abundance. Lower EBV avidity was associated with poorer quality of life and unrecovered status.
]]></description>
<dc:creator><![CDATA[ Joshi, R. V., Khan, R. M., Jackson, K. J., Ballouz, S., Jacka, B., Ni, L., Findell-Aghnatios, N., Aggarwal, A., Turville, S. G., Singh, M., Kim, K. W., Yau, C., Byrne, A., Brew, B. J., Dore, G. J., Darley, D. R., Matthews, G. V., Kelleher, A. D., Phetsouphanh, C. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.11.26367525</dc:identifier>
<dc:title><![CDATA[Altered herpesvirus-specific immune response is associated with long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.11.26367839v1?rss=1">
<title>
<![CDATA[
An observational study examining nasopharyngeal resistome evolution among children under the selective pressure of antibiotic exposure and hospitalisation for pneumonia in Malawi: A study protocol 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.11.26367839v1?rss=1
</link>
<description><![CDATA[
IntroductionAntimicrobial resistance (AMR) to first line antibiotics for pneumonia is a major global health problem, and AMR-attributable deaths are prevalent in sub-Saharan Africa. Improved data on how AMR develops and influences health outcomes in resource limited settings is crucial. The nasopharynx is a reservoir for pneumonia pathogens and their resistome, the genetic determinants of AMR. No study has explored whether human resistome composition in children with pneumonia is associated with health outcomes. This study will examine whether antibiotic treatment and hospital admission for pneumonia generate a persistent hospital-acquired nasopharyngeal resistome in children, and whether this is associated with re-hospitalisation.

MethodsThis is an observational case-control study, that will recruit 350 children aged 12-36 months from four groups in Blantyre, Malawi: healthy children in the community (healthy community), children with pneumonia treated in the community (community pneumonia), children hospitalised with pneumonia (hospital pneumonia) and children re-hospitalised with pneumonia (re-hospitalised pneumonia). Nasopharyngeal swabs will be taken at recruitment and 3-month follow-up study visits for metagenomic sequencing to characterise the nasopharyngeal microbiome and resistome; urine samples will be taken at recruitment for an antibiotic activity bioassay. Socio-demographic data, co-morbidities, pneumonia severity, antibiotic exposure and health outcomes will be recorded.

AnalysisCross-sectional comparisons between groups at recruitment will examine whether nasopharyngeal resistome (NPR) composition differs by pneumonia severity, antibiotic and healthcare exposure. Longitudinal comparisons within groups will assess the dynamics of NPR composition over time. The study is powered to detect a medium effect size (Cohens D = 0.505) change in the relative abundance of antibiotic resistance genes (ARGs) between all four groups. Primary outcomes are the difference in beta diversity (Bray-Curtis dissimilarity index), and relative abundance of ARG classes in the NPR. The primary objectives are to estimate the difference in diversity and relative abundance of the NPR between hospitalised pneumonia participants when compared to 1) healthy community and 2) community pneumonia participants, and to investigate whether participants re-hospitalised with pneumonia within a 3-month period have a persistent hospital-acquired NPR pattern.

Ethics and disseminationThe study has been approved by the Kamuzu University of Heath Sciences Research Ethics Committee (KUREC, formerly Malawi College of Medicine Research Ethics Committee; Ref: P.10/24-1200) and Liverpool School of Tropical Medicine Research Ethics Committee (LSTM REC; Ref: 24-076).

Trial registration numberISRCTN64027792

STRENGTHS AND LIMITATIONS OF THIS STUDYO_ST_ABSStrengthsC_ST_ABSO_LIStudy design that uses metagenomic deep sequencing to enable direct, concurrent comparison of nasopharyngeal microbiome (NPM) and resistome (NPR) composition between community and hospitalised paediatric populations with pneumonia in a resource-limited setting.
C_LIO_LIData on reported and urinary bioassay-detected antibiotic use prior to, and throughout the study, enabling detailed examination of antibiotic selective pressure on the NPR.
C_LIO_LIInvestigation of the association between NPR composition and adverse clinical outcomes from pneumonia.
C_LI

LimitationsO_LILimitations to this study include few sampling time points (two for community pneumonia and three for hospitalised pneumonia), which may not fully capture the impact of antibiotic exposure; the potential for residual confounding following adjustment for known potential confounders (e.g. age, sex, co-morbidities, household exposure to smoke and breastfeeding) in the association between resistome composition and adverse clinical outcomes, for which the authors have detailed statistical analysis measures; and ability to only determine association between NPR composition and adverse clinical outcomes, rather than causal inference, due to the case-control study design.
C_LI

SUMMARYO_ST_ABSWhat is already known on this topicC_ST_ABSThe nasopharynx is a reservoir for pneumonia pathogens and their genetic determinants of antibiotic resistance in children. Studies of nasopharyngeal microbiome composition have shown association with paediatric pneumonia severity and mortality.

What this study addsThis study will describe nasopharyngeal resistome (NPR) evolution under selective pressure of antibiotics and hospitalisation for paediatric pneumonia, and explore whether NPR composition is associated with health outcomes in a resource-limited setting.

How this study might affect research, practice or policyThis exploratory study could inform larger scale observational studies to examine the association between antibiotic resistance and health outcomes, by defining high-risk nasopharyngeal resistome composition, helping to determine the required sample size and contributing open-source bioinformatic pipelines. The study could also inform research for public health interventions, including antibiotic stewardship.
]]></description>
<dc:creator><![CDATA[ O'Connor, L., Kalizang'oma, A., Chimalizeni, Y., Meehan, C., Androga, G., Brown, C., Henrion, M., Chaguza, C., French, N., Heyderman, R. S., Kwambana-Adams, B. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.11.26367839</dc:identifier>
<dc:title><![CDATA[An observational study examining nasopharyngeal resistome evolution among children under the selective pressure of antibiotic exposure and hospitalisation for pneumonia in Malawi: A study protocol]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.11.26367845v1?rss=1">
<title>
<![CDATA[
Impact of vaccination coverage and timing on recent yellow fever outbreaks in Africa: a modeling study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.11.26367845v1?rss=1
</link>
<description><![CDATA[
BackgroundMultiple recent yellow fever (YF) outbreaks have occurred despite a highly effective vaccine. Increasing vaccination coverage and decreasing response times have been key components of the Eliminate Yellow Fever Epidemics (EYE) strategy. However, the combined impacts of these factors on YF outbreaks, especially since implementation of the EYE strategy in 2017, remain uncertain.

MethodsWe developed mathematical models to simulate the effects of vaccination coverage and timing, calibrating them to recent YF outbreaks in Ghana (2021-2022) and South Sudan (2023-2024). We then projected YF morbidity and mortality under different EYE strategy thresholds for vaccination coverage and timing.

ResultsIn Ghana, where reactive vaccination was observed at 22 days with an estimated 70% baseline coverage, modeled delays of 60 and 120 days yielded 62 (95% uncertainty interval [UI] 30-119) and 281 (95% UI 59-927) additional severe cases, respectively. Increasing baseline vaccination coverage to 80% averted an estimated 20 severe cases (95% UI 14-25). In South Sudan, where reactive vaccination occurred at 61 days with estimated 50% baseline coverage, shortening the response time to 20 days and increasing baseline coverage to 80% averted an estimated 80 (95% UI 68-91) and 95 severe cases (95% UI 80-112) independently - or 103 severe cases (95% UI 85-120) if combined.

ConclusionIncreasing baseline YF vaccination coverage to at least 80% can avert substantial morbidity from YF outbreaks. Decreasing vaccination response time for reactive vaccination can provide additional benefit.

SummaryGaps in immunization and delays in reactive vaccination contribute to yellow fever outbreaks, but specific impacts are unknown. This modeling analysis estimates the individual and combined effects of vaccination coverage and response timing on recent yellow fever outbreaks in Africa.
]]></description>
<dc:creator><![CDATA[ Judson, S., Pennington, J., Haring, C., Stephan, N., Yuson, M., Lee, S., Kenu, E., Dowdy, D. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.11.26367845</dc:identifier>
<dc:title><![CDATA[Impact of vaccination coverage and timing on recent yellow fever outbreaks in Africa: a modeling study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1">
<title>
<![CDATA[
Sentinel Event Surveillance to Identify Threats to SMC Effectiveness: Association Between Breakthrough Infections, SMC Uptake, Adherence and Parasite Drug Resistance 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.10.26367777v1?rss=1
</link>
<description><![CDATA[
Seasonal malaria chemoprevention (SMC) is an important malaria prevention strategy used widely in areas of West Africa with highly seasonal transmission. Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) to young children during the high-transmission season substantially reduces malaria morbidity and mortality. SMC has recently been introduced in northern Kenya, where pastoralist communities experience intense malaria transmission. However, implementation in this setting presents unique challenges, including population mobility, vast distances, dispersed settlements, and high levels of parasite resistance to SP in parts of the region. Effective surveillance is needed to identify gaps in SMC delivery and uptake and to monitor threats to program effectiveness.

We implemented an innovative sentinel-site surveillance approach in which every malaria case among SMC-eligible children at selected health facilities was investigated to identify gaps in SMC delivery, uptake, and effectiveness. We also assessed the prevalence of parasite alleles associated with SP and AQ resistance and examined their relationship with SMC uptake.

Household travel was substantially more common than caregiver refusal among reported reasons for missing an SMC cycle. More than one-third of children presenting with malaria had missed their most recent SMC cycle, while 15% were within a few days of receiving the next scheduled cycle. The prevalence of SP resistance mutations was considerably lower than reported in other parts of East Africa: only 13.4% of infections carried the quintuple mutant haplotype IRNI/GEAA (PfDHFR 51I, 59R, 108N, PfDHPS 437G, 540E) associated with high level resistance to SP. However, the prevalence of resistance-associated mutations was higher among children who had recently received SMC. The allele associated with reduced susceptibility to AQ was not detected.

Sentinel surveillance identified geographic and implementation gaps in real time, allowing program managers to target SMC distribution and community sensitization. Although the prevalence of resistance-associated mutations that could threaten SPAQ effectiveness was low, evidence of intrahost selection among children who had received SMC suggests that continued molecular surveillance will be important as SMC is scaled up in northern Kenya. This sentinel surveillance approach provides a practical framework for monitoring SMC implementation in remote, highly mobile populations while simultaneously tracking emerging threats to SPAQ effectiveness.
]]></description>
<dc:creator><![CDATA[ Wakoli, D. M., Rotich, B., Mbugua, E., Van Hulle, S., Kipkoech, J., Abel, L., Katairo, T., Kimachas, E., Wesolowski, A., Conrad, M., Menya, D., OMeara, W. P. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.10.26367777</dc:identifier>
<dc:title><![CDATA[Sentinel Event Surveillance to Identify Threats to SMC Effectiveness: Association Between Breakthrough Infections, SMC Uptake, Adherence and Parasite Drug Resistance]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.08.26367568v1?rss=1">
<title>
<![CDATA[
Antifolate resistance markers and complexity of infection in children with sickle cell anaemia receiving malaria chemoprevention in Uganda: a molecular sub-study of the CHEMCHA randomised trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.08.26367568v1?rss=1
</link>
<description><![CDATA[
BackgroundSickle cell anaemia (SCA) is a major public health problem in Uganda. Monthly sulfadoxine-pyrimethamine (SP) remains the standard malaria chemoprevention regimen despite widespread antifolate resistance in East Africa. We assessed Pfdhfr and Pfdhps resistance mutations and the complexity of infection (COI) among children with SCA receiving malaria chemoprevention.

MethodsThis prospective study of antifolate resistance was nested within the CHEMCHA randomised controlled trial comparing monthly SP with weekly dihydroartemisinin-piperaquine (DP) for malaria chemoprevention. Participants were children with SCA aged 6 months to 15 years and attending Jinja and Kitgum hospitals in Uganda. Dried blood spots were collected at enrolment, study closeout, and during febrile episodes. Parasite DNA from microscopy-confirmed clinical malaria samples was genotyped by amplicon sequencing for Pfdhfr (N51I, C59R, S108N, and I164L) and Pfdhps (A437G, K540E, A581G, A613S, and A613T). COI was estimated using MOIRE.

ResultsComplete Pfdhfr/Pfdhps haplotypes were resolved for 7-28 isolates per site and time point, and COI was estimated for 67 samples. The quintuple mutant (Pfdhfr IRN/Pfdhps GE) accounted for 85.7-100% of isolates across sites and time points; A613S and A613T were not detected. Pfdhfr I164L was detected in 2/9 isolates in Jinja at baseline and 1/8 at endline. The Pfdhps A581G mutant allele was absent at baseline (0/44 isolates) but was found in 1/8 isolates in Jinja and 3/34 in Kitgum at endline, including quintuple-plus-581G (sextuple) haplotypes in 1/8 and 2/27 isolates, respectively. Most infections were monoclonal (51/67, 76.1%).

ConclusionsThe high prevalence of quintuple antifolate-resistant haplotypes and the detection of higher-level resistance markers, including emerging sextuple mutants carrying Pfdhfr I164L and Pfdhps A581G, call into question the continued use of SP for chemoprevention in children with SCA in Uganda and support evaluation of alternative regimens.
]]></description>
<dc:creator><![CDATA[ Nambatya, W., Ocan, M., Okek, E. J., Ndeezi, G., Kalibbala, D., Katairo, T., Bwanga, F., Nkosi-Gondwe, T., Kirikumwino, J., Ssenkusu, J., Tukwasibwe, S., Opoka, R., ter Kuile, F. O., Phiri, K. S., Idro, R. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.08.26367568</dc:identifier>
<dc:title><![CDATA[Antifolate resistance markers and complexity of infection in children with sickle cell anaemia receiving malaria chemoprevention in Uganda: a molecular sub-study of the CHEMCHA randomised trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.10.26367744v1?rss=1">
<title>
<![CDATA[
Phylogeography and transmission dynamics of the 2025-2026 Utah-Arizona measles outbreak: a retrospective genomic epidemiology study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.10.26367744v1?rss=1
</link>
<description><![CDATA[
BackgroundMeasles outbreaks are increasing in frequency globally as vaccine coverage decreases. During the 2025-26 Utah-Arizona border outbreak, identifying where and between whom transmission occurred was essential for directing control measures. However, epidemiological data alone are not sufficient to infer transmission patterns.

MethodsAs part of the local and state-wide outbreak investigation, we conducted amplicon-based whole genome sequencing on residual diagnostic samples from confirmed measles cases collected from June 15, 2025-April 30, 2026. We reconstructed viral dispersal across Utah using Bayesian phylogeographic analyses. We evaluated genetic distance thresholds for identifying recent transmission by comparing single nucleotide polymorphism (SNP)-based genetic clusters with known epidemiologic linkages. We then assessed pairwise exposures associated with genetically supported transmission linkage using logistic regression, accounting for network and spatial dependence between pairs.

FindingsWe generated 509 high-quality whole measles virus genomes from 913 patients. In 2025, most viral dispersal events (67.9%) originated in Southwest Utah and Mohave County, Arizona, where the first cases were reported. By 2026, most viral spread (60.5%) occurred outside of this area. A threshold of 0 SNPs identified epidemiologically linked pairs of individuals with a sensitivity of 77.4% and specificity of 92.3%. Household membership (odds ratio (OR): 219.10, 95% credible interval (CI): 112.66-325.53), participation in the same sport (OR: 15.19, 95% CI: 9.75-20.63), and attendance at the same school (OR: 51.5, 95% CI: 36.38-66.61) were independently associated with transmission linkage. Increasing distance between households was associated with reduced odds of linkage (OR: 0.46: 95% CI 0.44-0.48).

InterpretationRepeated introductions of measles virus from southwestern Utah seeded transmission elsewhere in Utah, with household, school, and sports exposures contributing to onward transmission. Validated genome-based linkage measures can complement contact tracing by helping public health teams identify likely transmission networks and prioritize investigation when resources are constrained.

FundingEpidemiology and Laboratory Capacity (ELC) program at the CDC

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed and medRxiv as of October 6, 2026 for studies about measles genomic or molecular epidemiology, measles virus transmission modelling, and application of whole genome sequencing of measles virus. English language search terms included "measles", "measles virus", "phylodynamic", "genomic epidemiology", "molecular epidemiology", "transmission modelling", "transmission dynamics", "sequencing", "whole genome sequencing", and "WGS". Previous studies have primarily utilized N450 sequencing in their outbreak assessments, including phylogenetic and phylogeographic analyses. More recent studies have utilized whole genome sequencing to perform phylogenetic analysis and have overlaid some epidemiological data to assess transmission. To our knowledge, no studies have combined epidemiological and whole genome sequencing data to quantitatively assess drivers of transmission.

Added value of this studyWe integrate detailed epidemiological data with whole genome sequencing, providing a comprehensive analysis of geographic spread and key drivers of transmission in the Utah-Arizona border outbreak. We generated whole genome sequences for 56% of confirmed cases, high sequence coverage that enabled us to identify an appropriate genomic threshold and approximate direct transmission links. Our findings illustrate a change in geographic transmission as the outbreak persisted and highlighted household, school, and sports based transmission as primary sources of exposure.

Implications of all the available evidenceOur findings demonstrate the utility of measles surveillance using whole genome sequencing paired with epidemiological data. As measles outbreaks increase in frequency, new approaches are needed to characterize the key drivers of transmission. By integrating epidemiologic and genomic data, we identified genomic thresholds for transmission that can be applied in settings where extensive epidemiologic data are unavailable. Ultimately, utilizing genomic and epidemiological data together will strengthen our surveillance of future measles outbreaks.
]]></description>
<dc:creator><![CDATA[ Marye, A., Oakeson, K., Lan, Y., Warren, J. L., Francis, D., Hicks, L., Walter, K. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.10.26367744</dc:identifier>
<dc:title><![CDATA[Phylogeography and transmission dynamics of the 2025-2026 Utah-Arizona measles outbreak: a retrospective genomic epidemiology study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.10.26367219v1?rss=1">
<title>
<![CDATA[
Personalized HLA-aware TCR measure predicts the risk of symptomatic SARS-CoV-2 infection following booster vaccination 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.10.26367219v1?rss=1
</link>
<description><![CDATA[
HLA-driven heterogeneity and limitations of live T cell functional assays routinely thwart assessment of cell-mediated immunity in vaccination trials. To address this, we developed a T-cell receptor (TCR)-based measure of immunogen recognition and evaluated it in COV-BOOST, a third-dose COVID-19 vaccine trial, during the Delta and Omicron waves (2021-2022, United Kingdom). We estimated HLA-aware Spike-reactive T cell (HA-TS) breadth from participant HLA genotypes, TCR{beta} repertoires, and a novel SARS-CoV-2 Spike HLA-linked reference catalog. Higher post-boost HA-TS breadth was associated with lower symptomatic infection risk (HR 0.58, 95% CI 0.39-0.86). This association persisted after adjustment for neutralizing antibody titers and IFN-{gamma} responses. Examination of HA-TS across prior studies showed that it reflects participant genotype, exposure intensity, and time from exposure to sampling. These findings highlight the possibility that estimates of antigen-specific T cell repertoire breadth could serve as a correlate of protection to accelerate vaccine development.
]]></description>
<dc:creator><![CDATA[ Mayer-Blackwell, K., Hussain, K., Ebrahimi, N., Ford, E. S., Dale, A. P., Alderson, J., Bibi, S., Munro, A. P. S., Faust, S. N., Liu, X., Lambe, T., Voysey, M., Fiore-Gartland, A. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.10.26367219</dc:identifier>
<dc:title><![CDATA[Personalized HLA-aware TCR measure predicts the risk of symptomatic SARS-CoV-2 infection following booster vaccination]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.10.26367734v1?rss=1">
<title>
<![CDATA[
An agent-based model of Epstein-Barr virus transmission and vaccination 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.10.26367734v1?rss=1
</link>
<description><![CDATA[
Epstein-Barr virus (EBV) infects over 90% of adults worldwide, causing infectious mononucleosis (IM) in adolescents and young adults and contributing to multiple malignancies. Despite its global burden, population-level transmission modeling of EBV remains limited. We present the first population-level agent-based model (ABM) of EBV transmission. The model is implemented with 10,000 agents and calibrated to age-specific seroprevalence data from the US National Health and Nutrition Examination Survey. Two complementary calibration methods are evaluated, each with its own distinct advantages: Approximate Bayesian Computation (ABC) and Bayesian Optimization with Expected Quantile Improvement (BO-EQI). ABC directly yields an approximate distribution of transmission parameters for propagation through vaccination scenarios. BO-EQI uses a limited simulation budget to identify well-fitting parameter vectors, particularly as the number of fitted parameters increases. We estimate parameter uncertainty at each resolution in a separate Gaussian-kernel posterior analysis, which requires additional simulations and an explicit model for discrepancies between simulated and observed prevalence. As an illustrative application, we simulate the population-level effect of hypothetical EBV vaccines over a 100-year projection horizon. Similar to a previous modeling study, our results suggest that vaccine durability is at least as critical as efficacy, and that a vaccine with direct protection against only EBV may persistently shift IM burden to older ages, an effect our longer simulation horizon reveals to be a durable equilibrium shift rather than a transient cohort phenomenon. These findings highlight the importance of careful vaccine target product profile design; in particular, our results suggest that dual efficacy against both EBV infection and IM progression represents the most promising achievable target profile, and should be a core design objective for next-generation EBV vaccines.
]]></description>
<dc:creator><![CDATA[ Amoako, B., Huang, Z., Thommes, E. W., Hare, W., Cojocaru, M. G. ]]></dc:creator>
<dc:date>2026-11-12</dc:date>
<dc:identifier>doi:10.64898/2026.11.10.26367734</dc:identifier>
<dc:title><![CDATA[An agent-based model of Epstein-Barr virus transmission and vaccination]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.09.26367673v1?rss=1">
<title>
<![CDATA[
Seasonality and spatial heterogeneity of confirmed malaria in Senegal (2009-2025): consistency with VECTRI simulations driven by ten bias-adjusted CMIP6 models and projected changes 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.09.26367673v1?rss=1
</link>
<description><![CDATA[
BackgroundMalaria transmission in Senegal is seasonal and spatially heterogeneous, but the consistency of dynamical malaria models with routine surveillance has rarely been tested with monthly subnational data.

MethodsWe analysed monthly confirmed cases from the National Malaria Control Programme (PNLP) regional database (14 regions, 2009-2025) and reports of the 79 health districts (2016-2025). Ten bias-adjusted NEX-GDDP-CMIP6 models (1995-2014; SSP2-4.5 and SSP5-8.5 to 2100) were evaluated against CHIRPS rainfall; VECTRI was driven by MRI-ESM2-0, the model closest to the ensemble median change.

ResultsNational incidence averaged 24.5 cases per 1,000 per year without trend over 2009-2024, but increased in Kedougou, Kolda and Tambacounda, which reported 58.7 % of cases for 11.3 % of the population. The test positivity rate (TPR) decreased from 22.5 % in 2016 to 16.2 % in 2024. Based on the seasonal centre of gravity, observed cases lagged the entomological inoculation rate (EIR) simulated by VECTRI by 1.06 months (95 % CI 0.88-1.23) and the lag was positive in 13 of 14 regions, but the regional differences in timing were not reproduced. Across 45 departments, the simulated EIR was correlated with the TPR (Spearman {rho} = 0.67, 95 % CI 0.47-0.79). In 2025, confirmed cases decreased by 55.7 % in the 34 districts of the long-lasting insecticidal net (LLIN) mass campaign against 9.7 % elsewhere. Under SSP5-8.5 in 2081-2100, the models projected +4.6 {degrees}C and -32 % annual rainfall, and the simulated EIR decreased by 35 % (p < 0.001).

ConclusionsVECTRI driven by bias-adjusted CMIP6 climate reproduces the timing of the malaria season and the gradient of transmission intensity in Senegal, but not the regional differences in timing. The TPR is a population-free indicator for model evaluation. Seasonal malaria chemoprevention calendars should account for the regional timing documented here; the projected changes in timing are small.
]]></description>
<dc:creator><![CDATA[ Diouf, I., Sambou Cissokho, M. J., Fall, P., Beye Gueye, A., Doucoure, E., Gaye, A. T. ]]></dc:creator>
<dc:date>2026-11-10</dc:date>
<dc:identifier>doi:10.64898/2026.11.09.26367673</dc:identifier>
<dc:title><![CDATA[Seasonality and spatial heterogeneity of confirmed malaria in Senegal (2009-2025): consistency with VECTRI simulations driven by ten bias-adjusted CMIP6 models and projected changes]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.09.26367649v1?rss=1">
<title>
<![CDATA[
Streamlined Point-of-Care Ultrasound Examination for Pulmonary Tuberculosis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.09.26367649v1?rss=1
</link>
<description><![CDATA[
BackgroundPoint-of-care ultrasound (POCUS) is a low-cost, radiation-free triage tool but lacks standardized acquisition protocols for tuberculosis (TB). We developed and evaluated a streamlined symmetric POCUS protocol for pulmonary TB in a high-burden setting.

MethodsUgandan participants aged [&ge;]13 years with confirmed pulmonary TB, household TB exposure, or a non-TB respiratory condition underwent an 18-position POCUS examination (12 lung zones and 6 pre-established extrapulmonary positions). Random Forest classifiers using prespecified pathologic features were developed in a fixed stratified 75/25 training/holdout split. All symmetric 2-, 4-, and 6-zone combinations were evaluated in training data. The best protocol of each size was locked and tested in the holdout set.

ResultsAmong 318 analyzed participants, 118 (37.1%) had pulmonary TB and 200 were TB-negative, including 102 with other respiratory conditions (ORC). The model-selected 6-zone protocol comprised bilateral anterior-superior, lateral-superior, and posterior-superior lung zones. For TB versus all TB-negative participants, the AUCs for the 6-zone, 12-zone, and 18-position protocols were 0.82 (95% CI, 0.73-0.92), 0.81 (0.70-0.92), and 0.81 (0.71-0.91), respectively (all P > 0.76). For TB versus ORC, AUCs were 0.81 (0.70-0.91), 0.85 (0.76-0.93), and 0.85 (0.76-0.94), respectively (all P > 0.45). The 2-zone protocol had a lower AUC than the 6-zone protocol for TB versus all TB-negative participants (P = 0.004). Shred sign, consolidation, and B-lines with irregular pleura were the strongest TB-associated findings.

ConclusionsA fixed 6-zone lung POCUS examination showed similar discrimination for TB to more comprehensive 12-lung-zone and 18-position protocols. This supports a simpler, scalable approach to TB triage.
]]></description>
<dc:creator><![CDATA[ Nakiyingi, L., Dhamdhere, R., Nate, W., Guevarra, K., Nabawanuka, E., Jovanovska Janeva, E., Shankman, R., Lwanga, E., Nakabugo, E., Nasinghe, E., Nakayenga, S., Astorga, G., Sridhar, T. A., Javvaji, H. K., Clark, E., Handler, D., Salgame, P., Alland, D., Joloba, M., Ellner, J., Madabhushi, A., Xie, Y. L. ]]></dc:creator>
<dc:date>2026-11-10</dc:date>
<dc:identifier>doi:10.64898/2026.11.09.26367649</dc:identifier>
<dc:title><![CDATA[Streamlined Point-of-Care Ultrasound Examination for Pulmonary Tuberculosis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.08.26367564v1?rss=1">
<title>
<![CDATA[
Impact of DENV-ZIKV cross-reactivity in Southeast Asia: A modelling study in Thailand 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.08.26367564v1?rss=1
</link>
<description><![CDATA[
Dengue virus (DENV) is endemic across Southeast Asia (SEA), where a large proportion of adults have been infected. Zika virus (ZIKV) has circulated in the region for decades but the extent of transmission remains unclear. Prior infection with one virus can protect against or enhance infection with the other, but the population-level consequences are unknown. We developed an age-structured DENV-ZIKV model with nine cross-reactivity assumptions combining cross-protection and subsequent enhancement, and simulated sustained co-circulation under changing Thai demography. Through cross-reactivity, DENV strongly shaped ZIKV transmission, whereas ZIKV had little effect on DENV transmission. Under cross-protection, ZIKV transmission occurred as infrequent outbreaks without changes in long-term ZIKV burden. When prior DENV infection enhanced both ZIKV infection and symptomatic risk, this burden roughly doubled. Population ageing raised the mean age of DENV and ZIKV cases by over 20 years, more than cross-reactivity did. Simulated ZIKV case ages were closer to those reported in Thailand in 2019-2023 under enhancement of ZIKV infection and symptoms. Over half of individuals aged 15-49 years remained ZIKV-naive under all assumptions, leaving many pregnancies at risk of congenital Zika syndrome. Interpreting ZIKV case counts in SEA requires joint consideration of cross-reactivity, demographic change and case detection.
]]></description>
<dc:creator><![CDATA[ Shi, Y., Senapati, A., Huang, A. T., Clapham, H. E. ]]></dc:creator>
<dc:date>2026-11-10</dc:date>
<dc:identifier>doi:10.64898/2026.11.08.26367564</dc:identifier>
<dc:title><![CDATA[Impact of DENV-ZIKV cross-reactivity in Southeast Asia: A modelling study in Thailand]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.06.26367448v1?rss=1">
<title>
<![CDATA[
Protocol for a controlled human infection with genetically modified Neisseria lactamica expressing the meningococcal vaccine antigens NadA and FHbp: The GM-Nlac Pilot Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.06.26367448v1?rss=1
</link>
<description><![CDATA[
IntroductionPrevious work has shown that experimentally induced colonisation with Neisseria lactamica (Nlac) is safe and associated with reduced meningococcal colonisation. This pilot study aims to establish the safety, induction of colonisation and immunogenicity following intranasal inoculation with a mixture of four strains of genetically modified Nlac (GM-Nlac). Each of these strains express meningococcal vaccine antigens present in current vaccines: Neisseria adhesin A (NadA) and one of four different variants of Factor H-binding protein (FHbp), the latter of which is specifically mutated to abrogate its ability to bind the human complement protein, Factor H.

Methods and analysisIn this controlled human infection model experiment, 10 healthy participants aged 18-45 years will be inoculated with a mixture of 4 strains of GM-Nlac (collectively referred to as the challenge agent, 4xrNlac). They will be followed up over 28 days to assess colonisation, immunogenicity and efficacy of eradication with a single oral dose of ciprofloxacin (500 mg). Participant contacts will also be recruited to assess for onward transmission of GM-Nlac.

Ethics and disseminationThis study involves the deliberate release of four genetically modified organisms, which has been approved by the Department for Environment, Food and Rural Affairs (reference: 25/R50/01). The clinical study has also been approved by South-Central Oxford A Research Ethics Committee and the Health Research Authority (reference: 26/SC/0072). All participants will provide written informed consent prior to enrolment. Findings of the study will be submitted for publication in a peer-reviewed scientific journal and for presentation at scientific conferences.

RegistrationThis study is registered on the ISRCTN registry with study registration number ISRCTN10930766

Strength and limitations of the studyO_ST_ABSStrengthsC_ST_ABSO_LIA platform controlled human infection model that will enable the study of human mucosal immune responses to single gene products of Neisseria meningitidis.
C_LIO_LIA pathfinder study that will guide potential future mucosal immunoprophylaxis.
C_LIO_LIRigorous protocol for safety evaluation of a deliberately released multistrain genetically modified live bacterial product.
C_LI

LimitationsO_LISmall exploratory pilot study.
C_LI
]]></description>
<dc:creator><![CDATA[ Chick, G., Gbesemete, D. F., Jump Salcedo, P., Wilson, M. W., Hill, A. R., Coutinho, T. J., Anderson, R., Elliott, R. S., Mohanraj, D., Cleary, D. W., Lucidarme, J., Borrow, R., Faust, S. N., Gorringe, A. R., Read, R. C., Dale, A. P., Laver, J. R. ]]></dc:creator>
<dc:date>2026-11-09</dc:date>
<dc:identifier>doi:10.64898/2026.11.06.26367448</dc:identifier>
<dc:title><![CDATA[Protocol for a controlled human infection with genetically modified Neisseria lactamica expressing the meningococcal vaccine antigens NadA and FHbp: The GM-Nlac Pilot Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.06.26367472v1?rss=1">
<title>
<![CDATA[
MB-CasFire™: A Plug-and-Play, Thermostable CRISPR Enzyme for Precise Nucleic Acid Detection 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.06.26367472v1?rss=1
</link>
<description><![CDATA[
CRISPR-based detection technologies have the potential to enable precise, rapid, and cost-effective diagnostic and biosurveillance solutions by pairing sensitive and specific nucleic acid detection with a simple workflow. Combining isothermal amplification and CRISPR detection in a single reaction as a "one-pot" detection method can meet these needs, but only if the CRISPR enzyme remains active at the temperatures and salt concentrations that isothermal amplification requires. Here we describe MB-CasFire, a CRISPR-Cas enzyme engineered from a naturally thermostable Cas12a for improved stability and performance, as a "plug-and-play" DETECTR(R) (DNA Endonuclease-Targeted CRISPR Trans Reporter) enzyme for sensitive and specific nucleic acid detection. MB-CasFire remains active at elevated temperatures in amplification buffers and supports one-pot detection with loop-mediated isothermal amplification (LAMP) and nicking enzyme amplification reaction (NEAR), eliminating transfers between amplification and readout, and increasing the signal-to-noise to enable precise nucleic acid detection. This method, called OnePot DETECTR, is also compatible with commercially available isothermal master mixes, including those from New England Biolabs, allowing assays to be assembled from standard reagents. Using MB-CasFire, we detected SARS-CoV-2 in nasal swab samples with a LAMP-based OnePot DETECTR assay and Neisseria gonorrhoeae in urine samples with a NEAR-based OnePot DETECTR assay. MB-CasFire also functioned in multiplex detection and single-nucleotide polymorphism discrimination assays for antibiotic resistance genotyping. These results support MB-CasFire as a versatile detection enzyme that simplifies assay architecture for CRISPR-based detection assays that amplify, recognize, and report the presence of nucleic acid targets in a single reaction without thermocycling.
]]></description>
<dc:creator><![CDATA[ Broughton, J. P., Alpay, E., Fantin, N. J., Ansaloni, S., Elsener, S., Jung, J. K., Zhang, Y., Madrid, I. Z., Shiigi, S. A., Rajan, S., Jain, I., Wright, W. D., Hendriks, C. G., Tymoshenko, S., Ratushna, V., Lee, S., Warner, M., Hong, R., Sui, X., Panchal, S., Garske, A. L., Miao, X., Chen, J. S. ]]></dc:creator>
<dc:date>2026-11-09</dc:date>
<dc:identifier>doi:10.64898/2026.11.06.26367472</dc:identifier>
<dc:title><![CDATA[MB-CasFire™: A Plug-and-Play, Thermostable CRISPR Enzyme for Precise Nucleic Acid Detection]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.07.26367494v1?rss=1">
<title>
<![CDATA[
Tuberculosis treatment outcome in Cameroon: a systematic review and meta-analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.07.26367494v1?rss=1
</link>
<description><![CDATA[
BackgroundTuberculosis (TB) remains a major public health challenge in Cameroon, yet national evidence on treatment outcomes across the full spectrum of routine care is limited. This systematic review and meta-analysis estimated pooled proportions of treatment success, mortality, treatment failure and loss to follow-up (LTFU) among TB patients in Cameroon, and identified predictors of unfavorable outcomes.

MethodsPubMed, Embase, Scopus, Web of Science, African Journals Online and the Cochrane Library were searched, supplemented by Google Scholar and reference-list screening. Observational studies conducted in Cameroon reporting at least one WHO-defined treatment outcome were eligible. Pooled proportions and adjusted odds ratios (AOR) were estimated with random-effects models meta-analysis. Data were analyzed using R Statistics version 4.6.1.

ResultsThirty-two studies (25 cohorts, 7 cross-sectional), conducted between 1998 and 2022 across six of Cameroons ten regions, were included. Pooled treatment success was 78.2% (95% CI: 73.8-82.1; 27 reports; 71,784 participants; I{superscript 2} = 98.2%), mortality 8.1% (95% CI: 5.5-11.7; 25 reports; 71,870 participants; I{superscript 2} = 97.8%), treatment failure 0.9% (95% CI: 0.5-1.4; 26 reports; 71,389 participants; I{superscript 2} = 89.1%) and LTFU 6.8% (95% CI: 5.0-9.1; 26 reports; 70,768 participants; I{superscript 2} = 98.6%). Mortality was highest in the South-West (16.2%) and among TB/HIV-coinfected patients (30.5%), and lowest among children (5.0%). Treatment success was lowest in the Littoral (71.1%) and among TB/HIV-coinfected patients (60.8%) and highest among multidrug-resistant TB (89.3%) and pediatric patients (86.8%). Treatment failure significantly declined from 2.9% before 2005 to 0.5% from 2020 onward (p < 0.001). Significant predictors of unfavorable outcomes were HIV positivity (AOR = 2.57; 95% CI: 1.86-3.55), previous TB treatment (AOR = 1.99; 95% CI: 1.40-2.84), male sex (AOR = 1.67; 95% CI: 1.45-1.92), age [&le;]40 years (AOR = 1.45; 95% CI: 1.06-1.98) and absence of antiretroviral therapy (AOR = 1.71; 95% CI: 1.15-2.54).

ConclusionsTB treatment outcomes in Cameroon remain suboptimal, with nearly one in five patients not achieving treatment success and high mortality among TB/HIV-coinfected individuals. Strengthening TB/HIV service integration, early antiretroviral therapy initiation, targeted support for previously treated patients and men, and improved retention in care are needed.

Systematic review registration numberCRD420261404490
]]></description>
<dc:creator><![CDATA[ Cheuyem, F. Z. L., Zefack, J. T., Tchamani, R., Achangwa, C., Mapouo, C. J. K., Tsapi, A. T., Minkandi, C. A. ]]></dc:creator>
<dc:date>2026-11-09</dc:date>
<dc:identifier>doi:10.64898/2026.11.07.26367494</dc:identifier>
<dc:title><![CDATA[Tuberculosis treatment outcome in Cameroon: a systematic review and meta-analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.07.26367521v1?rss=1">
<title>
<![CDATA[
Post-Vaccination COVID-19 Infection and Its Correlates among Residents of Chandra, Gazipur, Bangladesh: A Cross-Sectional Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.07.26367521v1?rss=1
</link>
<description><![CDATA[
BackgroundCOVID-19 vaccines are highly effective at preventing severe disease and death but post-vaccination (breakthrough) infections are still seen, especially with immune-evasive variants. There is some evidence at the community level from Bangladesh. The aim of this study was to estimate prevalence, clinical profile and correlates of post-vaccination COVID-19 infection in Chandra, Kaliakair, Gazipur, Bangladesh.

MethodsThis was a community-based cross-sectional study that included adults [&ge;]18 years of age with at least one dose of a COVID-19 vaccine from March 2021 to December 2022. The respondents were 300 people who were selected by multistage sampling technique and interviewed with a pretested semi-structured questionnaire. Demographic, vaccination history, post-vaccination infection, clinical features, preventive behaviours, knowledge and comorbidities data were gathered. The chi-square test was used to test the bivariate associations and multivariable binary logistic regression was used to identify independent correlates. A p value of < 0.05 was used to determine statistical significance. Ethical Approval took from the IRB board of SCMST.

ResultsAmong 300 participants (mean age 48.0 {+/-} 17.6 years; 52.0% male), 124 (41.3%) reported COVID-19 infection after vaccination. Of these, 24 (19.4%) were asymptomatic, 67 (54.0%) had mild disease, 24 (19.4%) had moderate disease, and 9 (7.3%) had severe disease; only 12 (9.7%) required hospitalisation. In multivariable analysis, rural residence (adjusted odds ratio [aOR] 4.87; 95% CI 2.42-9.79), poor mask use (aOR 2.28; 95% CI 1.31-3.97), poor physical distancing (aOR 2.74; 95% CI 1.55-4.86), poor hand hygiene (aOR 3.61; 95% CI 2.05-6.38), and diabetes (aOR 4.46; 95% CI 1.97-10.14) were independently associated with higher odds of infection, whereas receipt of a booster dose was protective (aOR 0.23; 95% CI 0.13-0.42).

ConclusionPost-vaccination infection was common but largely mild and hospitalisation was rare. The booster vaccination was protective and factors such as rural residence, poor preventive practices and diabetes were risk factors for infection. These results do reinforce the importance of booster doses coupled with ongoing preventive behaviour and targeted interventions for clinically vulnerable populations.
]]></description>
<dc:creator><![CDATA[ Al Hasan Pranto, A., Sushmita Zafar, S., Fakhruzzaman, M., Rahman, M. S., Akter, S., Taslima Meem, J., Sultana, R., Afridi, S. ]]></dc:creator>
<dc:date>2026-11-09</dc:date>
<dc:identifier>doi:10.64898/2026.11.07.26367521</dc:identifier>
<dc:title><![CDATA[Post-Vaccination COVID-19 Infection and Its Correlates among Residents of Chandra, Gazipur, Bangladesh: A Cross-Sectional Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.06.26367422v1?rss=1">
<title>
<![CDATA[
Molecular evolution of Andes virus lineages leading to recent human outbreaks 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.06.26367422v1?rss=1
</link>
<description><![CDATA[
Andes virus (ANDV) is exceptional among hantaviruses in its capacity for person-to-person transmission, but whether outbreaks reflect recent viral adaptation or emergence of pre-existing reservoir lineages remains unclear. We generated paired blood- and nasal-derived genomes from the MV Hondius outbreak and integrated them with a segment-linked collection of human- and rodent-derived ANDV sequences, including incomplete genomes. We developed a linkage-informed missing-segment framework that preserves isolate identity, sampling time, and cross-segment placement without imputing nucleotide states, enabling sensitivity analyses of patchy segment coverage. Across five human outbreaks, dated phylogenies placed outbreak lineages independently within geographically structured reservoir diversity, with closest sampled ancestry predating detection. Time-dependent-rate analyses indicated a deeper reservoir-associated history, while mutation reconstruction, selection tests, branch-rate comparisons, and structural mapping found no recurrent adaptive transition preceding human transmission. MV Hondius samples showed minimal consensus-level diversification. These results shift attention from repeated recent adaptation toward deeper lineage properties and ecological opportunity.
]]></description>
<dc:creator><![CDATA[ Sharma, C., Oversti, S., Stass, R., Lucaci, A. G., Audet, J., Safronetz, D., Zhao, L., Lythgoe, K., Katzourakis, A., Bowden, T. A., Lytras, S., Ghafari, M. ]]></dc:creator>
<dc:date>2026-11-09</dc:date>
<dc:identifier>doi:10.64898/2026.11.06.26367422</dc:identifier>
<dc:title><![CDATA[Molecular evolution of Andes virus lineages leading to recent human outbreaks]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.06.26365637v1?rss=1">
<title>
<![CDATA[
Electricity Free LAMP: A Protocol for Loop-Mediated Isothermal Amplification Using an Exothermic Chemical Reaction and Lyophilized Reagents 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.06.26365637v1?rss=1
</link>
<description><![CDATA[
Loop-mediated isothermal amplification (LAMP) offers a promising alternative to PCR for low-resource settings, but practical barriers remain. For example, there is often the need for reliable electricity, precision heating equipment, and cold-chain storage of reagents. Here, we describe a rudimentary but functional platform that integrates (i) a non-electric, chemically driven water bath capable of sustaining LAMP-relevant temperatures and (ii) lyophilized LAMP assays compatible with simple sample inputs such as diluted saliva or oral rinse. We demonstrate successful LAMP amplification under multiple heating configurations, including a thermos-based chemical bath and field-mimicking setups. This work provides proof-of-concept for a low-cost, portable molecular diagnostic workflow that minimizes infrastructure requirements while maintaining analytical performance.
]]></description>
<dc:creator><![CDATA[ Grandhe, K. K., Riedel, T. E. ]]></dc:creator>
<dc:date>2026-11-09</dc:date>
<dc:identifier>doi:10.64898/2026.11.06.26365637</dc:identifier>
<dc:title><![CDATA[Electricity Free LAMP: A Protocol for Loop-Mediated Isothermal Amplification Using an Exothermic Chemical Reaction and Lyophilized Reagents]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.06.26367418v1?rss=1">
<title>
<![CDATA[
On conducting diary-based social contact surveys to inform transmission models of close-contact infections: a systematic review and expert-informed questionnaire 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.06.26367418v1?rss=1
</link>
<description><![CDATA[
BackgroundDiary-based social contact surveys are widely used to parameterise transmission models of close-contact infections. However, variation in study design, contact definitions, and questionnaire content limits comparability across studies. These challenges became particularly evident during the COVID-19 pandemic, when rapid and repeated data collection was urgently needed, often without harmonised instruments. To address these challenges, we aimed to develop an expert-informed questionnaire and update the recommendations on conducting diary-based social contact studies previously proposed by Hoang et al. (2019).

Methods and findingsWe conducted a systematic review of diary-based social contact surveys published between 31 January 2018 and 25 September 2025 using PubMed and the Web of Science Core Collection, extracting information on study design, survey methodology, contact definitions, and survey items from available questionnaires. Methodological quality and reporting were assessed using an adapted AXIS tool, with results summarised for each criterion. In total, we identified 129 studies across 62 countries, with most studies conducted during the COVID-19 pandemic (59.7% in 2021-2022). Retrospective reporting (86.0%) and non-probability sampling (77.5%) were largely adopted and became increasingly common during the pandemic, while non-paper-based data collection rose sharply from 2021 onwards. Across 36 retrievable questionnaires from general-population surveys, we identified 54 survey items. An online assessment involving 26 experts informed the classification of these items according to their perceived importance, resulting in an expert-informed questionnaire comprising 22 core items. Based on our findings, we updated previous recommendations on sampling, survey methods, contact definitions, behavioural change, essential contact information, and data governance.

ConclusionsThis study provides an expert-informed questionnaire and updated recommendations to support harmonised social contact data collection, improve comparability across studies, and strengthen preparedness for future public health emergencies.
]]></description>
<dc:creator><![CDATA[ Loedy, N., Lumia, G., Di Domenico, L., Suer, J., Jit, M., Melegaro, A., Funk, S., Backer, J. A., Grijalva, C. G., Paolotti, D., Verbiest, J., Ratmann, O., Coletti, P., Dan, S., Colizza, V., Beutels, P., Willem, L., Abrams, S., Hens, N. ]]></dc:creator>
<dc:date>2026-11-08</dc:date>
<dc:identifier>doi:10.64898/2026.11.06.26367418</dc:identifier>
<dc:title><![CDATA[On conducting diary-based social contact surveys to inform transmission models of close-contact infections: a systematic review and expert-informed questionnaire]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.06.26367404v1?rss=1">
<title>
<![CDATA[
Molecular typing and characterisation of antimicrobial resistance determinants of Neisseria gonorrhoeae among symptomatic individuals in the Eastern Cape, South Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.06.26367404v1?rss=1
</link>
<description><![CDATA[
BackgroundAntimicrobial resistance in Neisseria gonorrhoeae threatens gonorrhoea treatment, while surveillance is constrained by limited culture capacity. We evaluated multi-antigen sequence typing (NG-MAST) and targeted real-time PCR for molecular epidemiology and detection of antimicrobial resistance-associated determinants directly from clinical specimens.

MethodsWe analysed 235 N. gonorrhoeae-positive stored DNA extracts from symptomatic individuals in South Africa. NG-MAST sequence types were obtained directly or from whole-genome sequences (WGS) of paired cultured isolates. Real-time PCR targeted fluoroquinolone resistance-associated mutations (RAMs) in parC and gyrA and macrolide RAMs in the 23S rRNA gene. Results were compared with WGS and with phenotypic susceptibility results from paired isolates.

ResultsNG-MAST sequence types were obtained for 200/235 (85.1%) specimens and were diverse, with ST21253 predominating (n=26). At least one gyrA or parC mutation was detected by real-time PCR in 110/193 (57.0%) specimens. Compared with WGS, positive agreement was 81.2% for parC and 97.0% for gyrA, and negative agreement 100% and 95.8%, respectively. Among 65 ciprofloxacin-resistant isolates, RAMs were detected in 60 (92.3%) by real-time PCR and 61 (93.8%) by WGS; four had no RAM detected by either method. The 23S rRNA C2611T mutation was detected by both methods in one isolate (azithromycin MIC, 8 mg/L); no A2059G mutations were detected.

ConclusionsGonococcal sequence types were diverse, fluoroquinolone RAMs were common, and the assessed macrolide RAMs were rare. Real-time PCR applied directly to specimen DNA agreed well with WGS, but the targeted markers did not fully predict ciprofloxacin susceptibility, supporting complementary molecular and phenotypic approaches.
]]></description>
<dc:creator><![CDATA[ Mdingi, M. M., Kullin, B., Jung, H., Mitchev, N., Peters, R. P. ]]></dc:creator>
<dc:date>2026-11-08</dc:date>
<dc:identifier>doi:10.64898/2026.11.06.26367404</dc:identifier>
<dc:title><![CDATA[Molecular typing and characterisation of antimicrobial resistance determinants of Neisseria gonorrhoeae among symptomatic individuals in the Eastern Cape, South Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.11.05.26367381v1?rss=1">
<title>
<![CDATA[
EIN-RECAP: Evidence-Grounded Multi-Agent Summarization and Retrieval of Infectious-Disease Expert Discussions 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.11.05.26367381v1?rss=1
</link>
<description><![CDATA[
Infectious disease experts exchange practical knowledge through clinical discussions, but identifying relevant information across years of conversations is difficult. These discussions often contain differing opinions and emerging observations that are not yet reflected in published evidence. We present EIN-RECAP, an AI-assisted platform developed with Emerging Infections Network (EIN) experts and deployed in beta to summarize and search historical discussions. The system combines retrieval-grounded summarization, citation validation, and hybrid search while distinguishing published evidence from community experience. We evaluated summarization methods across 3,185 threads and conducted blinded expert review on a recent subset. Although a multi-agent workflow achieved stronger automated scores, experts favored a simpler generation pipeline and identified repetition, inaccuracies, and overconfident recommendations in the more complex system. This feedback motivated an ensemble that improved discussion coverage and key clinical points on nine high-disagreement threads, although retrieval relevance remained a limitation. Our findings demonstrate the importance of expert involvement in clinical AI development and show why automated evaluation alone is insufficient to guide system selection.
]]></description>
<dc:creator><![CDATA[ Choudhuri, A., Zhong, Y., Beekmann, S., Hodges, J., Jha, K., Segre, A. M., Adhikari, B., Polgreen, P. M. ]]></dc:creator>
<dc:date>2026-11-06</dc:date>
<dc:identifier>doi:10.64898/2026.11.05.26367381</dc:identifier>
<dc:title><![CDATA[EIN-RECAP: Evidence-Grounded Multi-Agent Summarization and Retrieval of Infectious-Disease Expert Discussions]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-11-06</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
